Rights and permissions
About this article
Cite this article
Alemtuzumab superior to IFN-β-1a for relapsing-remitting MS. Inpharma Wkly. 1506, 9 (2005). https://doi.org/10.2165/00128413-200515060-00020
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-200515060-00020